Floatz Rating
CC44/100
Confidence
Indicative
Sponsor
University of Chicago
Modality
UNKNOWN
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03810703CT.gov Differential Responses to Drugs and Sweet Tastes | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bipolar II Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| D-Amphetamine (this asset) | University of Chicago | P1 | CC · 44 |
| Lurasidone | Massachusetts General Hospital | P4 | BBB |
| VENLOR | Stanley Medical Research Institute | P4 | BB |
| Dexmedetomidine | BioXcel Therapeutics Inc | P3 | BB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Joshua Rosenblat | P4 | BB |
| Quetiapine | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Lamotrigine | University Hospital Bispebjerg and Frederiksberg | P4 | BB |
| Valproic Acid | National Cheng-Kung University Hospital | P4 | BB |
| Lithium, Elemental | University Hospital Bispebjerg and Frederiksberg | P4 | BB |
+19 more in the Bipolar II Disorder cohort
Other indications for D-Amphetamine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizoaffective Disorder | — | P2 | B · 57 |
| Post-Traumatic Stress Disorder | — | P2 | CCC · 53 |
| Schizophrenia | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. D-Amphetamine in Bipolar II Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/d-amphetamine-bipolar-ii-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →